Syneos Health (SYNH) announced a strategic partnership with Haystack Health, a Roivant Health (ROIV) portfolio company developing advanced Artificial Intelligence and Natural Language Processing solutions, to improve the identification and enrollment of patients for clinical trials. The combined capabilities of Syneos Health and Haystack Health will more effectively and efficiently identify and match clinical trial opportunities for patients. For sponsors and sites, this partnership will deliver valuable research tools and workflow efficiencies that result in improved timelines and increased patient recruitment. Initially, these new data solutions will only be available for Syneos Health sites in the US, with a focus on oncology and immunology. "The challenges of enrolling patients in clinical trials are well documented. Protocol complexity and specificity in precision medicine have made patient recruitment even more difficult. Haystack Health offers an advanced solution leveraging AI to match patients to trials while preserving privacy," said Baba Shetty, President, Technology & Data Solutions, Syneos Health. "We’re thrilled to be working closely alongside the Haystack Health team to innovate in this critical area for patients, sponsors and science."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SYNH:
- Syneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial Research
- Syneos Health and Haystack Health Partner to Accelerate Clinical Trials with AI
- Cryoport announces new strategic partnership with Syneos Health
- Syneos Health downgraded to Underweight from Overweight at Barclays
- Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab